Mylan N.V. (MYL) Issues FY17 Earnings Guidance

Mylan N.V. (NASDAQ:MYL) issued an update on its FY17 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $4.30-4.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.12. The company issued revenue guidance of $11.5-12.5 billion, compared to the consensus revenue estimate of $12.46 billion.

Mylan N.V. (NASDAQ MYL) traded up 0.52% during trading on Friday, hitting $30.72. 7,185,271 shares of the company’s stock traded hands. The company’s 50 day moving average price is $36.12 and its 200 day moving average price is $38.80. Mylan N.V. has a 52-week low of $29.39 and a 52-week high of $49.09. The company has a market cap of $16.47 billion, a PE ratio of 24.83 and a beta of 1.27.

Mylan N.V. (NASDAQ:MYL) last released its earnings results on Wednesday, August 9th. The company reported $1.10 EPS for the quarter, missing the Zacks’ consensus estimate of $1.18 by $0.08. The business had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $3 billion. Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The company’s revenue for the quarter was up 15.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.16 earnings per share. Analysts expect that Mylan N.V. will post $4.52 earnings per share for the current year.

MYL has been the topic of a number of recent analyst reports. Barclays PLC upgraded Mylan N.V. from an equal weight rating to an overweight rating and lifted their target price for the stock from $47.00 to $50.00 in a research note on Monday, May 22nd. BMO Capital Markets initiated coverage on Mylan N.V. in a research note on Monday, May 1st. They set an outperform rating and a $50.00 target price on the stock. Cantor Fitzgerald initiated coverage on Mylan N.V. in a research note on Friday, June 16th. They set a neutral rating and a $41.00 target price on the stock. Royal Bank Of Canada set a $41.00 price objective on Mylan N.V. and gave the company a hold rating in a research note on Sunday, July 16th. Finally, Zacks Investment Research cut Mylan N.V. from a hold rating to a sell rating in a research note on Monday, May 15th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $47.73.

In related news, President Rajiv Malik sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $40.00, for a total value of $1,000,000.00. Following the completion of the sale, the president now owns 799,855 shares in the company, valued at approximately $31,994,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Anthony Mauro sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the sale, the insider now owns 140,653 shares of the company’s stock, valued at approximately $5,626,120. The disclosure for this sale can be found here. 0.69% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by BNB Daily and is the sole property of of BNB Daily. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.baseball-news-blog.com/2017/08/19/mylan-n-v-myl-issues-fy17-earnings-guidance-updated.html.

Mylan N.V. Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply